JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Longitudinal Study of Postconcussion Syndrome: Not Everyone Recovers.

We examined recovery from postconcussion syndrome (PCS) in a series of 285 patients diagnosed with concussion based on international sport concussion criteria who received a questionnaire regarding recovery. Of 141 respondents, those with postconcussion symptoms lasting less than 3 months, a positive computed tomography (CT) and/or magnetic resonance imaging (MRI), litigants, and known Test of Memory Malingering (TOMM)-positive cases were excluded, leaving 110 eligible respondents. We found that only 27% of our population eventually recovered and 67% of those who recovered did so within the first year. Notably, no eligible respondent recovered from PCS lasting 3 years or longer. Those who did not recover (n = 80) were more likely to be non-compliant with a do-not-return-to-play recommendation (p = 0.006) but did not differ from the recovered group (n = 30) in other demographic variables, including age and sex (p ≥ 0.05). Clustergram analysis revealed that symptoms tended to appear in a predictable order, such that symptoms later in the order were more likely to be present if those earlier in the order were already present. Cox proportional hazards model analysis showed that the more symptoms reported, the longer the time to recovery (p = 7.4 × 10-6 ), with each additional symptom reducing the recovery rate by approximately 20%. This is the first longitudinal PCS study to focus on PCS defined specifically as a minimum of 3 months of symptoms, negative CT and/or MRI, negative TOMM test, and no litigation. PCS may be permanent if recovery has not occurred by 3 years. Symptoms appear in a predictable order, and each additional PCS symptom reduces recovery rate by 20%. More long-term follow-up studies are needed to examine recovery from PCS.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app